Cargando…

Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials

BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiazzo, Elisabetta, Rezig, Asma O.M., Bruzzese, Dario, Ialenti, Armando, Cicala, Carla, Cleland, John G.F., Guzik, Tomasz J., Maffia, Pasquale, Pellicori, Pierpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719379/
https://www.ncbi.nlm.nih.gov/pubmed/34979235
http://dx.doi.org/10.1016/j.phrs.2021.106053
_version_ 1784624925125902336
author Caiazzo, Elisabetta
Rezig, Asma O.M.
Bruzzese, Dario
Ialenti, Armando
Cicala, Carla
Cleland, John G.F.
Guzik, Tomasz J.
Maffia, Pasquale
Pellicori, Pierpaolo
author_facet Caiazzo, Elisabetta
Rezig, Asma O.M.
Bruzzese, Dario
Ialenti, Armando
Cicala, Carla
Cleland, John G.F.
Guzik, Tomasz J.
Maffia, Pasquale
Pellicori, Pierpaolo
author_sort Caiazzo, Elisabetta
collection PubMed
description BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. METHODS: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. RESULTS: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. CONCLUSIONS: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not.
format Online
Article
Text
id pubmed-8719379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87193792022-01-03 Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials Caiazzo, Elisabetta Rezig, Asma O.M. Bruzzese, Dario Ialenti, Armando Cicala, Carla Cleland, John G.F. Guzik, Tomasz J. Maffia, Pasquale Pellicori, Pierpaolo Pharmacol Res Article BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. METHODS: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. RESULTS: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. CONCLUSIONS: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not. Elsevier 2022-02 /pmc/articles/PMC8719379/ /pubmed/34979235 http://dx.doi.org/10.1016/j.phrs.2021.106053 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Caiazzo, Elisabetta
Rezig, Asma O.M.
Bruzzese, Dario
Ialenti, Armando
Cicala, Carla
Cleland, John G.F.
Guzik, Tomasz J.
Maffia, Pasquale
Pellicori, Pierpaolo
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title_full Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title_fullStr Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title_full_unstemmed Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title_short Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
title_sort systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with covid-19, sars, mers or influenza: a systematic review and meta-analysis of randomised trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719379/
https://www.ncbi.nlm.nih.gov/pubmed/34979235
http://dx.doi.org/10.1016/j.phrs.2021.106053
work_keys_str_mv AT caiazzoelisabetta systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT rezigasmaom systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT bruzzesedario systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT ialentiarmando systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT cicalacarla systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT clelandjohngf systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT guziktomaszj systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT maffiapasquale systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials
AT pellicoripierpaolo systemicadministrationofglucocorticoidscardiovascularcomplicationsandmortalityinpatientshospitalisedwithcovid19sarsmersorinfluenzaasystematicreviewandmetaanalysisofrandomisedtrials